Sign up to save your podcasts
Or
Share B-Cell Malignancies: Why Not All BTK Inhibitors Are Created Equal
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
B-Cell Malignancies: Why Not All BTK Inhibitors Are Created Equal
Join our expert faculty as they discuss next-generation BTK inhibitors, with a focus on specificity, efficacy, and tolerability.
Credit available for this activity expires: 11/16/2022
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/962783?src=mkm_podcast_addon_962783
View all episodes
By Medscape Podcasts
4
77 ratings
Join our expert faculty as they discuss next-generation BTK inhibitors, with a focus on specificity, efficacy, and tolerability.
Credit available for this activity expires: 11/16/2022
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/962783?src=mkm_podcast_addon_962783
More shows like Keeping Current
View all
JAMA Editors' Summary
137 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
497 Listeners
Diabetes Core Update
102 Listeners
This Week in Cardiology
881 Listeners
The Bob Harrington Show
13 Listeners
One-on-One with Eric Topol
17 Listeners
Mayo Clinic Talks
288 Listeners
The Curbsiders Internal Medicine Podcast
3,337 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
Annals On Call Podcast
194 Listeners
JAMA Medical News
88 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
366 Listeners
Medicine and the Machine
61 Listeners
Keeping Current CME
25 Listeners
Cardionerds: A Cardiology Podcast
431 Listeners
The Curious Clinicians
370 Listeners